CVS Stock Recent News
CVS LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CVS Health Corporation ("CVS Health Corporation") (NYSE:CVS) concerning possible violations of federal securities laws. The U.S. Department of Justice filed a complaint on May 1, 2025, against insurance broker organizations, including CVS, alleging that "insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments in the insurers' Medicare Advantage plans.
Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94).
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against CVS Health Corporation (“CVS” or the “Company”) (NYSE:CVS). The investigation concerns whether CVS and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
Activist investor Glenview Capital said on Tuesday it reduced its holdings in CVS Health by 3.75 million shares after the insurer posted "healthy" first-quarter results and raised annual forecast.
NEW YORK , May 6, 2025 /PRNewswire/ -- One year ago, we established a concentrated position in shares of CVS Health (NYSE: CVS). Since our purchases in May 2024, CVS shares have generated a total return of 25% reflecting initial progress in the long-term cultural and operational turnaround underway at the Company.
CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.